Vanguard Capital Management
NRXP icon

Vanguard Capital Management’s NRX Pharmaceuticals NRXP Stock Holding History

Vanguard Capital Management’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.62M Buy
1,618,159
+457,975
+39% +$1.51M ﹤0.01% 3013
2026
Q1 		$2.47M Buy
+1,160,184
New +$2.34M ﹤0.01% 3295

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Capital Management's NRXP Position: Q2 2026 in Review

Vanguard Capital Management increased its NRX Pharmaceuticals (NRXP) stake by 39% in Q2 2026, buying an estimated $1.51M and bringing the position to 1,618,159 shares worth $6.62M. The position accounts for ﹤0.01% of the portfolio, ranked #3013.

Vanguard Capital Management first reported a position in NRXP in Q1 2026 and has held it in 2 quarters since. 46 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • Vanguard Capital Management held 1,618,159 shares of NRX Pharmaceuticals worth $6.62M as of Q2 2026.
  • Vanguard Capital Management bought 457,975 NRX Pharmaceuticals shares in Q2 2026, an estimated $1.51M.
  • NRX Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3013 holding.
  • Vanguard Capital Management first reported a position in NRX Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 46 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.